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introduction: Recurrent pericarditis (RP) is a common complication of acute pericarditis, with 30% recurrence after first attack.. Steroids are 
associated with increased recurrence of pericarditis with known major side effects. Cardiac MR (CMR) has been used to assess inflammation and 
management. The aim of study is to assess the role of CMR-guided therapy in RP compare to standard therapy.
method and results: We evaluated 570 consecutive patients who developed recurrence following the first attack of pericarditis who were all 
treated with colchicine and NSAIDs as first treatment. 250 patients treated with medications without CMR (group 1), and 257 patients had CMR-
guided therapy (group 2). Both groups had similar baseline characteristics (table 1), and with similar follow-up period. (Table 1). Patients in group 1 
had higher number of steroid pulse therapy (p= 0.003) (defined as prednisone 50 mg orally daily for 10 days then tapered over 4 weeks), and higher 
overall total milligram of steroid administered as compared to those in group 2 (p= 0.001). Recurrence rate and pericaridocentesis were lower in 
group 2 as well (p<0.0001). There was no difference in incidence of constrictive pericarditis, or pericardiectomy among groups
conclusion: CMR-guided therapy modulates the management of recurrent pericarditis, which can decrease recurrence rate and the exposure to 
steroids. Larger prospective randomized multicenter study is necessary to validate these findings. 
Table 1. Baseline characteristics of patients with recurrent pericarditis (n = 145)
(Group 1) Managed Without MRI
(n = 250)
(Group 2) Managed With MRI
(n = 257)
P
Demographics
Mean age (SD), y 48 (14) 47 (13) 0.84
Caucasian, 130 (52) 123 (48) 0.37
Men, n (%) 132 (52.8) 123 (47.9) 0.28
Mean follow-up (SD), months 16.3 (16.2) 17 (17.9) 0.97
Co-morbidities
Hypertension, n (%) 91(36.4) 94 (36.6) 1.0
DM, n (%) 20 (8) 17 (6.6) 0.61
CAD, n (%) 19 (7.6) 21 (8.2) 0.87
CHF, n (%) 7 (2.8) 8 (3.1) 1.0
Valve disease, n (%) 40 (16) 53 (20.6) 0.20
Atrial Fibrillation, n (%) 24 (9.6) 23 (8.9) 0.87
Etiology
Idiopathic etiology, n (%) 180 (72) 181 (70.4) 0.76
PPS, n (%) 25 (10) 29 (11.3) 0.66
Other, n (%) 45 (18) 47 (18) 1.0
Medications
Colchicine, n (%) 250 (100) 257 (100) 1.0
NSAID, n (%) 250 (100) 257 (100) 1
Statin use, n (%) 81 (32.4) 89 (34.6) 0.63
Outcome
Mean WSR (0 - 15) (SD), mm/hr 32.3 (27.9) 32.0 (27.2) 0.89
# steroid pulse, n (SD) 2.41 (1.06) 0.63 (0.91) 0.00
Mean total steroid (SD), mg 1695.4 (1166.09) 486 (546.4) 0.00
# or recurrence, n (SD) 3.6 (2.18) 1.19 (1.2) 0.00
Constriction, n (%) 17 (6.8) 19 (7.4) 0.86
Pericardiocentesis, n (%) 40 (16) 15 (5.8) 0.00
Pericardial Window, n (%) 44 (17.6) 56 (21.8) 0.26
Pericardiectomy, n (%) 14 (5.6) 12 (4.7) 0.69
Death, n (%) 2 (0.8) 1 (0.4) 0.61
DM, diabetes mellitus; CAD, coronary artery disease; CHF, congestive heart failure; PPS, post-pericardiotomy syndrome; NSAID, non-steroidal anti-inflammatory drugs.
